FDA Accepts IND for Cue Biopharma's CUE-102 in the treatment of Wilms' Tumor 1 (WT1)

Cue Biopharma, Inc. CUE received the U.S. Food and Drug Administration (FDA) acceptance of the Investigational New Drug (IND) application for the evaluation of CUE-102 in the treatment of Wilms' Tumor 1 (WT1)-positive recurrent/metastatic cancers.

This IND acceptance enables the dose escalation of Phase 1 trial to start dosing at 1 mg/kg, supported by the safety and tolerability data from the CUE-101 (the first biologic from the CUE-100 series) trial.

Ken Pienta, M.D., acting chief medical officer, commented, "We believe CUE-102 provides a significant opportunity to address a high unmet medical need in a wide variety of WT1-positive malignancies including colorectal, pancreatic and lung, and potentially offers a tolerable and more effective treatment option to patients in need. We believe CUE-102 has the potential to change the treatment landscape for WT1-positive patients and are very pleased to now begin evaluating its potential benefit in the clinic." 

The FDA clearance marks significant milestone for Cue Biopharma in its multi-target strategic collaboration with LG Chem Life Sciences, to develop multiple Immuno-STAT biologics focused in the field of oncology.

Cue Biopharma is currently trading down 12 percent at $3.70.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareFDAGeneral
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!